CGEM Cullinan Oncology Inc

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL.

  • Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York, NY on Tuesday, November 11, 2025, at 3:20 p.m. ET.



  • Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 8:00 a.m. ET.



  • The Company will host an in-person event for analysts and institutional investors on Monday, December 8, at 8:00 p.m. ET, during the 2025 ASH Annual Meeting. The event will follow the oral presentation of results from the Phase 1 study of CLN-049 in patients with AML or MDS earlier that morning (Presentation ID 768). Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations ().



Webcasts of the fireside chats and the ASH event will be available under the Events and Presentations section of the Company’s investor relations website at .

About Cullinan Therapeutics

 (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at , and follow us on  and .

Contacts:

Investor Relations

Nick Smith

+1 401.241.3516

Media

Rose Weldon

+1 215.801.7644



EN
10/11/2025

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Qua...

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerat...

5h / 49m 1 EN
Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
8h / 26m 8h / 26m 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026, at 1:1...

February 24, 2026 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026...

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET. A webc...

February 18, 2026 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenhei...

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11:00 a.m. ET....

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch